Cerebrovascular reactivity to carbon dioxide in alzheimer's disease

Journal of Alzheimer's Disease

Volumn 35, Issue 3, 2013, Pages 427-440

  Glodzik, Lidia ^a   Randall, Catherine ^a   Rusinek, Henry ^a   De Leon, Mony J ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; carbon dioxide; cognitive impairment; vascular; vasoreactivity

Indexed keywords

ACETAZOLAMIDE; AMYLOID BETA PROTEIN; CARBON DIOXIDE; CHOLINERGIC RECEPTOR STIMULATING AGENT; ENDOTHELIN 1; MESSENGER RNA; MYOCARDIN; SERUM RESPONSE FACTOR; THROMBIN; XENON 133;

ALZHEIMER DISEASE; BOLD SIGNAL; CHEMOREACTIVITY; HUMAN; KORSAKOFF PSYCHOSIS; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENILE DEMENTIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPIN LABELING; TRANSCRANIAL DOPPLER;

EID: 84880249296     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-122011     Document Type: Review

References (113)

1. Anslie PN, Duffin J (2009) Integration of cerebrovascular CO2 reactivity and chemoreflex control of breathing: Mechanisms of regulation, measurement, and interpretation. Am J Physiol Regul Integr Comp Physiol 296, R1473-R1495.
2. Peebles KC, Richards AM, Celi M, McGrattan K, Murrell CJ, Anslie PN (2008) Human cerebral arteriovenous vasoactive exchange during alterations in arterial blood gases. J Appl Physiol 105, 1060-1068.
3. Ogoh S, Hayashi N, Inagaki M, Anslie PN, Miyamoto T (2008) Interaction between the ventilatory and cerebrovascular responses to hypo- and hypercapnia at rest and during exercise. J Physiol 586, 4327-4338.
4. Rodell AB, Aanerud J, Braendgaard H, Gjedde A (2012) Low residual CBF variability in Alzheimer's disease after correction for CO(2) effect. Front Neuroenergetic 4, 8.
5. Ito H, Kanno I, Fukuda H (2005) Human cerebral circulation: Positron emission tomography studies. Ann Nucl Med 19, 65-74.
6. Claassen JA, Zhang R, Fu Q, Witkowski S, Levine L, BD (2007) Transcranial Doppler estimation of cerebral blood flow and cerebrovascular conductance during modified rebreathing. J Appl Physiol 102, 870-877.
7. Willie CK, Macleod DB, Shaw AD, Smith KJ, Tzeng YC, Eves ND, Ikeda K, Graham J, Lewis NC, Day TA, Anslie PN (2012) Regional brain blood flow in man during acute changes in arterial blood gases. J Physiol 590, 3261-3275.
8. Peebles K, Celi L, McGrattan K, Murrell C, Thomas K, Ainslie PN (2007) Human cerebrovascular and ventilatory CO2 reactivity to end-tidal, arterial and internal jugular vein PCO2. J Physiol 584, 347-357.
9. Wang X,Wu J, Li L, Chen F,Wang R, Jiang C (2003) Hypercapnic acidosis activates KATP channels in vascular smooth muscles. Circ Res 92, 1225-1232.
10. Brian JE (1998) Carbon dioxide and the cerebral circulation. Anesthesiology 88, 1365-1386.
11. Lavi S, Egbarya R, Lavi R, Jacob G (2003) Role of nitric oxide in the regulation of cerebral blood flow in humans: Chemoregulation versus mechanoregulation. Circulation 107, 1901-1905.
12. Lavi S, Gaitini D, Milloul V, Jacob G (2006) Impaired cerebral CO2 vasoreactivity: Association with endothelial dysfunction. Am J Physiol Heart Circ Physiol 291, H1856-H1861.
13. Mirro R, Lowery-Smith R, Armstead WR, Shibata M, Zuckerman LS, Leffler CW (1992) Cerebral vasoconstriction in response to hypocapnia is maintained after ischemia/reperfusion injury in newborn pigs. Stroke 23, 1613-1616.
14. Ogoh S, Anslie PN (2009) Cerebral blood flow during exercise: Mechanisms of regulation. J Appl Physiol 107, 1370-1380.
15. Boles Ponto LL, MagnottaVA,Moser DJ, Duff KM, Schultz SK (2006) Global cerebral blood flow in relation to cognitive performance and reserve in subjects with mild memory deficits. Mol Imaging Biol 8, 363-372.
16. Chollet F, Celsis P, Clanet M, Guirard-Chaumeil B, Rascol A, Marc-Vergnes JP (1989) SPECT study of cerebral blood flow reactivity after acetazolamide in patients with transient ischemic attacks. Stroke 20, 458-464.
17. De Reuck J, Decoo D, Hasenbroeckx MC, Lamont B, Santens P, Goethals P, Strijckmans K, Lemahieu I (1999) Acetazolamide vasoreactivity in vascular dementia: A positron emission tomographic study. Eur Neurol 41, 31-36.
18. Groschel K, Terborg C, Riecker A, Witte OW, Kastrup A (2007) Effects of physiological aging and cerebrovascular risk factors on the hemodynamic response to brain activation: A functional transcranial doppler study. Clin Neurophysiol 118, e35-e36.
19. Settakis G, Pall D, Molnar C, Bereczki D, Csiba L, Fulesdi B (2003) Cerebrovascular reactivity in hypertensive and healthy adolescents: TCD With vasodilatory challenge. J Neuroimaging 13, 106-112.
20. FujiwaraY, Mizuno T, Okuyama C, NagakaneY,Watanabe-Hosomi A, Kondo M, Kuriyama N, Tokuda T, Matsushima S, Nishimura T, Nakagawa M (2012) Simultaneous impairment of intracranial and peripheral artery vasoreactivity in CADASIL patients. Cerebrovasc Dis 33, 128-134.
21. Claassen JA, Zhang R (2011) Cerebral autoregulation in Alzheimer's disease. J Cereb Blood Flow Metab 31, 1572-1577.
22. Kennelly SA, Lawlor B, Kenny RA (2009) Blood pressure and the risk for dementia - A double edged sword. Aging Res Rev 8, 61-70.
23. Nagai M, Hoshide S, Kario K (2010) Hypertension and dementia. Am J Hypertens 23, 116-124.
24. Murray AD, Staff RT, Shenkin SD, Deary IJ, Starr JM, Whalley LJ (2005) Brain white matter hyperintensities: Relative importance of vascular risk factors in nondemented elderly people. Radiology 237, 251-257.
25. Usman K, Porteous L, Hassan A, Markus HS (2007) Risk factor profile of cerebral small vessel disease and its subtypes. J Neurol Neurosurg Psychiatr 78, 702-706.
26. Pase MP, Grima NA, Sarris J (2011) The effects of dietary and nutrient interventions on arterial stiffness: A systematic review. Am J Clin Nutr 93, 446-454.
27. Iadecola C (2004) Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 5, 347-360.
28. de la Torre JC (2009) Carotid artery ultrasound and echocardiography testing to lower the prevalence of Alzheimer's disease. J Stroke Cerebrovasc Dis 18, 319-328.
29. Farkas E, Luiten PGM (2001) Cerebral microvascular pathology in aging and Alzheimer's disease. Pro Neurobiol 64, 575-611.
30. Zlokovic BV (2011) Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 12, 723-738.
31. Kivipelto M, Helkala EL, Hanninen T, Laakso MP, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A(2001) Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study. Neurology 56, 1683-1689.
32. Moore PM, Baker GA (1997) Psychometric properties and factor structure of the Wechsler Memory Scale-Revised in a sample of persons with intractable epilepsy. J Clin Exp Neuropsychol 19, 897-905.
33. Kilander L, Nyman H, Boberg M, Hansson L, Lithell H (1998) Hypertension is related to cognitive impairment: A 20-year follow-up of 999 men. Hypertension 31, 780-786.
34. Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kareholt I,Winblad B, Helkala E-L, Tuomilehto J, Soininen H, NissinenA (2005) Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 62, 1556-1560.
35. Craft S, Watson GS (2004) Insulin and neurodegenerative disease: Shared and specific mechanisms. Lancet Neurol 3, 169-178.
36. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet Neurol 368, 387-403.
37. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239-259.
38. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M (1996) [beta]-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380, 168-171.
39. Crawford F, Suo Z, Fang C, MullanM(1998) Characteristics of the in vitro vasoactivity of beta-amyloid peptides. Exp Neurol 150, 159-168.
40. Said SI, Raza S, Berisha HI (1998) Enhancement of systemic and pulmonary vasoconstriction by beta-amyloid peptides and its suppression by vasoactive intestinal peptide. Ann N Y Acad Sci 865, 582-585.
41. Khalil Z, Chen HB, HelmeRD(1996) Mechanisms underlying the vascular activity of [beta]-amyloid protein fragment ([beta]A425-35) at the level of skin microvasculature. Brain Res 736, 206-216.
42. Niwa K, Porter VA, Kazama K, Cornfield D, Carlson GA, Iadecola C (2001)Abeta-peptides enhance vasoconstriction in cerebral circulation.AmJ Physiol Heart Circ Physiol 281, H2417-H2424.
43. Niwa K, Kazama K, Younkin L, Younkin SG, Carlson GA, Iadecola C (2002) Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am J Physiol Heart Circ Physiol 283, H315-H323.
44. Niwa K, Kazama K, Younkin SG, Carlson GA, Idecola C (2002) Alterations in cerebral blood flowand glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol Dis 9, 61-68.
45. Shin HK, Jones PB, Garcia-Alloza M, Borrelli L, Greenberg SM, Bacskai BJ, Frosch MP, Hyman BT, Moskowitz MA, Ayata C (2007) Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. Brain 130(Pt 9), 2310-2319.
46. Palmer JC, Barker R, Kehoe PG, Love S (2012) Endothelin-1 is elevated in Alzheimer's disease and upregulated by amyloid-beta. J Alzheimers Dis 29, 853-861.
47. Kawanabe Y, Nauli SM (2011) Endothelin. Cell Mol Life Sci 68, 195-203.
48. Eckman EA, Reed DK, Eckman CB (2001) Degradation of the Alzheimer's amyloid beta peptide by endothelinconverting enzyme. J Biol Chem 276, 24540-24548.
49. Palmer JC, Baig S, Kehoe PG, Love S (2009) Endothelinconverting enzyme-2 is increased in Alzheimer's disease and up-regulated by Abeta. Am J Pathol 175, 262-270.
50. Luo J, Grammas P (2010) Endothelin1 is elevated in Alzheimer's disease brain microvessels and is neuroprotective. J Alzheimers Dis 21, 887-896.
51. Madonna R, De Caterina R, Willerson JT, Geng YJ (2011) Biologic function and clinical potential of telomerase and associated proteins in cardiovascular tissue repair and regeneration. Eur Heart J 32, 1190-1196.
52. Chow N, Bell RD, Deane R, Streb JW, Chen J, Brooks A, Van Nostrand W, Miano JM, Zlokovic BV (2007) Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer's phenotype. Proc Natl Acad Sci U S A 104, 823-828.
53. Bell RD, Deane R, Chow N, Long X, Sagare A, Singh I, Streb JW, Guo H, Rubio A, Van NW, Miano JM, Zlokovic BV (2009) SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat Cell Biol 11, 143-153.
54. Hirano K (2007) The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 27, 27-36.
55. Hirano K, Hirano M (2010) Current perspective on the role of the thrombin receptor in cerebral vasospasm after subarachnoid hemorrhage. J Pharmacol Sci 114, 127-133.
56. Maki J, Hirano M, Hoka S, Kanaide H, Hirano K (2010) Involvement of reactive oxygen species in thrombin-induced pulmonary vasoconstriction. Am J Respir Crit Care Med 182, 1435-1444.
57. Arai T, Miklossy J, Klegeris A, Guo JP, McGeer PL (2006) Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain. J Neuropathol Exp Neurol 65, 19-25.
58. EngelbergH(2004) Pathogenic factors in vascular dementia and Alzheimer's disease. Multiple actions of heparin that probably are beneficial. Dement Geriatr Cogn Disord 18, 278-298.
59. MhatreM,Nguyen A, Kashani S,PhamT, Adesina A, Grammas P (2004) Thrombin, a mediator of neurotoxicity and memory impairment. Neurobiol Aging 25, 783-793.
60. Grammas P, Samany PG, Thirumangalakudi L (2006) Thrombin and inflammatory proteins are elevated in Alzheimer's disease microvessels: Implications for disease pathogenesis. J Alzheimers Dis 9, 51-58.
61. YinX, right J, allT, Rammas P (2010) Brain endothelial cells synthesize neurotoxic thrombin in Alzheimer's disease. Am J Pathol 176, 1600-1606.
62. Claassen JA, Jansen RW (2006) Cholinergically mediated augmentation of cerebral perfusion in Alzheimer's disease and related cognitive disorders: The cholinergic-vascular hypothesis. J Gerontol A Biol Sci Med Sci 61, 267-271.
63. van Beek AH, Claassen JA (2011) The cerebrovascular role of the cholinergic neural system in Alzheimer's disease. Behav Brain Res 221, 537-542.
64. Sato A, Sato Y, Uchida S (2002) Regulation of cerebral cortical blood flow by the basal forebrain cholinergic fibers and aging. Auton Neurosci 96, 13-19.
65. Vaucher E, Hamel E (1995) Cholinergic basal forebrain neurons project to cortical microvessels in the rat: Electron microscopic study with anterogradely transported Phaseolus vulgaris leucoagglutinin and choline acetyltransferase immunocytochemistry. J Neurosci 15, 7427-7441.
66. Tong XK, Hamel E (2000) Basal forebrain nitric oxide synthase (NOS)-containing neurons project to microvessels and NOS neurons in the rat neocortex: Cellular basis for cortical blood flow regulation. Eur J Neurosci 12, 2769-2780.
67. Uchida S, Hotta H (2009) Cerebral cortical vasodilatation mediated by nicotinic cholinergic receptors: Effects of old age and of chronic nicotine exposure. Biol Pharm Bull 32, 341-344.
68. Davies P, Maloney AJF (1976) Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2, 1403.
69. Craig LA, Hong NS, McDonald RJ (2011) Revisiting the cholinergic hypothesis in the development of Alzheimer's disease. Neurosci Biobehav Rev 35, 1397-1409.
70. Lojkowska W, Ryglewicz D, Jedrzejczak T, Minc S, Jakubowska T, Jarosz H, Bochynska A (2003) The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia. J Neurol Sci 216, 119-126.
71. Li W, Antuono PG, Xie C, Chen G, Jones JL, Ward BD, Franczak MB, Goveas JS, Li SJ (2012) Changes in regional cerebral blood flow and functional connectivity in the cholinergic pathway associated with cognitive performance in subjects with mild Alzheimer's disease after 12-week donepezil treatment. Neuroimage 60, 1083-1091.
72. Imamura K, Wada-Isoe K, Kowa H, Tanabe Y, Nakashima K (2008) The effect of donepezil on increased regional cerebral blood flow in the posterior cingulate cortex of a patient with Parkinson's disease dementia. Neurocase 14, 271-275.
73. Nobili F, Vitali P, Canfora M, Girtler N, De LC, Mariani G, Pupi A, Rodriguez G (2002) Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients. Clin Neurophysiol 113, 1241-1248.
74. Venneri A, Shanks MF, Staff RT, Pestell SJ, Forbes KE, Gemmell HG, Murray AD (2002) Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. NeuroReport 13, 83-87.
75. Honer WG, Prohovnik I, Smith G, Lucas LR (1988) Scopolamine reduces frontal cortex perfusion. J Cereb Blood Flow Metab 8, 635-641.
76. Prohovnik I, Arnold SE, Smith G, Lucas LR (1997) Physostigmine reversal of scopolamine-induced hypofrontality. J Cereb Blood Flow Metab 17, 220-228.
77. Bahro M, Molchan SE, Sunderland T, Herscovitch P, Schreurs BG (1999) The effects of scopolamine on changes in regional cerebral blood flow during classical conditioning of the human eyeblink response. Neuropsychobiology 39, 187-195.
78. Bar KJ, Boettger MK, Seidler N, Mentzel HJ, Terborg C, SauerH(2007) Influence of galantamine on vasomotor reactivity in Alzheimer's disease and vascular dementia due to cerebral microangiopathy. Stroke 38, 3186-3192.
79. Wyss-Coray T, Rogers J (2012) Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2, a006346.
80. Kamer AR, Dasanayake AP, Craig RG, Glodzik-Sobanska L, Brys M, de Leon MJ (2008) Alzheimer's disease and peripheral infections: The possible contribution from periodontal infections, model and hypothesis. J Alzheimers Dis 13, 437-449.
81. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T (2007) Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13, 1359-1362.
82. Pezzzini A, Del Zotto E, Volonghi I, Giossi A, Costa P, Padovani A (2009) Cerebral amyloid angiopathy: A common cause of cerebral hemorrhage. Curr Med Chem 16, 2498-2513.
83. Vonsattel J-P, Myers RH, Hedley-Whyte ET, Ropper AH, Bird ED, Richardson EP Jr. (1991) Cerebral amyloid angiopathy without and with cerebral hemorrhages: A comparative histological study. Ann Neurol 30, 637-649.
84. Scheibel AB, Duong T, JacobsR(1989) Alzheimer's disease as a capillary dementia. Ann Med 21, 103-107.
85. Jellinger KA, Attems J (2006) Prevalence and impact of cerebrovascular pathology in Alzheimer's disease and parkinsonism. Acta Neurol Scand 114, 38-46.
86. Miyakawa T, Katsuragi S, Higuchi Y, Yamashita K, Kimura T, Teraoka K, Ono T, Ishizuka K (1997) Changes of microvessels in the brain with Alzheimer's disease. Ann N Y Acad Sci 826, 428-432.
87. Hashimura T, Kimura T, Miyakawa T (1991) Morphological changes of blood vessels in the brain with Alzheimer's disease. Jpn J Psychiatry Neurol 45, 661-665.
88. Buee L, Hof PR, Delacourte A (1997) Brain microvascular changes in Alzheimer's disease and other dementias. Ann N Y Acad Sci 826, 7-24.
89. Simard D, Olesen J, Paulson OB, Lassen NA, Skinhoj E (1971) Regional cerebral blood flow and its regulation in dementia. Brain 94, 273-288.
90. Hachinski VC, Iliff LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, Russell RWR, Symon L (1975) Cerebral blood flow in dementia. Arch Neurol 32, 632-637.
91. Yamaguchi F, Meyer JS, Yamamoto M, Sakai F, Shaw T (1980) Noninvasive regional cerebral blood flow measurements in dementia. Arch Neurol 37, 410-418.
92. Bonte FJ, Devous MD Sr., Reisch JS, Ajmani AK, Weiner MF, Hom J, Tintner R (1989) The effect of acetazolamide on regional cerebral blood flow in patients with Alzheimer's disease or stroke as measured by single-photon emission computed tomography. Invest Radiol 24, 99-103.
93. Stoppe G, Schultze R, Kogler A, Staedt J, Munz DL, Emrich D, Ruther E (1995) Cerebrovascular reactivity to acetazolamide in (senile) dementia of Alzheimer's type: Relationship to disease severity. Dementia 6, 73-82.
94. Knapp WH, Dannenberg C, Marschall B, Zedlick D, Loschmann K, Bettin S, Barthel H, Seese A (1996) Changes in local cerebral blood flow by neuroactivation and vasoactivation in patients with impaired cognitive function. Eur J Nucl Med 23, 878-888.
95. Pavics L, Grunwald F, Reichmann K, Sera T, Ambrus E, Horn R, Hartmann A, Menzel C, Csernay L, Biersack HJ (1998) rCBF SPECT and the acetazolamide test in the evaluation of dementia. Nucl Med Rev Cent East Eur 1, 13-19.
96. Oishi M, Mochizuki Y, Takasu T (1999) Regional differences in cerebrovascular reactivity to acetazolamide in Alzheimer's disease. J Clin Neurosci 6, 380-381.
97. Raichle ME, Martin WRW, Herscovitch P, Mintum MA, Markham J (1983) Brain blood flow measured with intravenous 0-15H2O. 2. Implementation and validation. J Nucl Med 24, 790-798.
98. Herscovitch P, Markham J, Raichle ME (2013) Brain blood flow measured with intravenous H2O15. I. Theory and error analysis. J Nucl Med 24, 782-789.
99. Kuwabara Y, Ichiya Y, Otsuka M, Masuda K, Ichimiya A, Fujishima M (1992) Cerebrovascular responsiveness to hypercapnia in Alzheimer's dementia and vascular dementia of the Binswanger type. Stroke 23, 594-598.
100. Jagust WJ, Eberling JL, Reed BR, Mathis CA, Budinger TF (1997) Clinical studies of cerebral blood flowin Alzheimer's disease. Ann NY Acad Sci 826, 254-262.
101. Huber P, Handa J (1967) Effect of contrast material, hypercapnia, hyperventilation, hypertonic glucose and papaverine on the diameter of the cerebral arteries. Angiographic determination in man. Invest Radiol 2, 17-32.
102. GillerCA(2003) The emperor has no clothes: Velocity, flow, and the use of TCD. J Neuroimag 13, 97-98.
103. Vincenzini E, Ricciardi MC, Altieri M, Puccinelli F, Bonaffini N, Di Piero V, Lenzi GL (2007) Cerebrovascular reactivity in degenerative and vascular dementia: Atranscranial Doppler study. Eur Neurol 58, 84-89.
104. Likitjaroen Y, Suwanwela NC, Phanthumchinda K (2009) Vasoreactivity induced by acetazolamide in patients with vascular dementia versus Alzheimer's disease. J Neurol Sci 283, 32-35.
105. Silvestrini M, Pasqualetti P, Baruffaldi R, Bartolini M, HandoukY, Matteis M, Moffa F, Provinciali L,Vernieri F (2006) Cerebrovascular reactivity and cognitive decline in patients with Alzheimer disease. Stroke 37, 1010-1015.
106. Yezhuvath US, Uh J, Cheng Y, Martin-Cook K, Weiner M, Diaz-Arrastia R, van OM, Lu H (2012) Forebrain-dominant deficit in cerebrovascular reactivity in Alzheimer's disease. Neurobiol Aging 33, 75-82.
107. Cantin S, Villien M, Moreaud O, Tropres I, Keignart S, Chipon E, Le Bas JF,Warnking J, KrainikA(2011) Impaired cerebral vasoreactivity to CO2 in Alzheimer's disease using BOLD fMRI. Neuroimage 58, 579-587.
108. Glodzik L, Rusinek H, Brys M, Tsui WH, Switalski R, Mosconi L, Mistur R, Pirraglia E, De Santi S, Li Y, Goldowsky A, de Leon M (2011) Framingham cardiovascular risk profile correlates with impaired hippocampal and cortical vasoreactivity to hypercapnia. J Cereb Blood Flow Metab 31, 671-679.
109. Rusinek H, Brys M, Glodzik L, Switalski R, Tsui WH, Haas F, McGorty K, Chen Q, de Leon MJ (2011) Hippocampal blood flow in normal aging measured with arterial spin labeling at 3T. Magn Reson Med 65, 128-137.
110. de Leon MJ, George AE, Stylopoulos LA, Smith G, Miller DC (1989) Early marker for Alzheimer's disease: The atrophic hippocampus. Lancet 2, 672-673.
111. de Leon MJ, Golomb J, George AE, Convit A, Tarshish CY, McRae T, De Santi S, Smith G, Ferris SH, Noz M, Rusinek H (1993) The radiologic prediction of Alzheimer's disease: The atrophic hippocampal formation. Am J Neuroradiol 14, 897-906.
112. Rusinek H, De Santi S, Frid D, Tsui W, Tarshish C, Convit A, de Leon MJ (2003) Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging. Radiology 229, 691-696.
113. Albuquerque ML, Lowery-Smith L, Hsu P, Parfenova H, Leffler CW (1995) Low CO2 stimulates inositol phosphate turnover and increased inositol 1,4,5-trisphosphate levels in piglet cerebral microvascular smooth muscle cells. Proc Soc Exp Biol Med 209, 14-19.